Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Definium Therapeutics (NASDAQ:DFTX) issued its quarterly earnings data on Thursday. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Upcoming catalysts: Company expects three Phase 3 readouts in 2026 with Emerge (MDD) top-line in late Q2 2026, Voyage (GAD) in early Q3, and Panorama in H2 — plus Ascend dosing beginning in early Q2.
• Voyage completed a blinded sample-size re-estimation with no increase required; observed lower variability (SD ~6.7 vs planned 10) and lower non-evaluable rate, implying substantially higher power to detect the prespecified treatment effect.
• Strong balance sheet: year-end cash, equivalents and investments of $411.6M, which management says should fund operations into 2028 and supports pre-commercial investments and launch prep.
• Pipeline diversification: First participant dosed in Phase 2a of DT-402 (R‑MDMA) for autism spectrum disorder with initial data expected later in 2026, adding an earlier-stage program beyond DT120 ODT.
• Rising burn and loss: 2025 net loss widened to $183.8M (from $108.7M) driven by higher R&D and G&A spend, reflecting accelerated development and commercialization spending.

Definium Therapeutics Stock Down 1.9%

Shares of NASDAQ DFTX traded down $0.33 during midday trading on Thursday, hitting $17.29. The stock had a trading volume of 1,123,415 shares, compared to its average volume of 1,836,327. The business’s 50 day moving average is $15.47 and its 200-day moving average is $12.72. Definium Therapeutics has a 52 week low of $4.70 and a 52 week high of $18.70. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31. The company has a market cap of $1.70 billion, a P/E ratio of -8.48 and a beta of 2.57.

Analyst Ratings Changes

Several research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Jefferies Financial Group began coverage on Definium Therapeutics in a research note on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target on the stock. Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a report on Thursday, January 29th. Finally, Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Definium Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $34.20.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 25,791 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer directly owned 778,477 shares in the company, valued at $10,236,972.55. The trade was a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the sale, the insider owned 425,025 shares in the company, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 42,667 shares of company stock worth $561,071 in the last three months. Insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the period. BNP Paribas Financial Markets boosted its holdings in Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares during the last quarter. Caxton Associates LLP bought a new stake in Definium Therapeutics in the 3rd quarter worth approximately $126,000. Mercer Global Advisors Inc. ADV grew its position in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after purchasing an additional 2,079 shares during the period. Finally, Scientech Research LLC purchased a new stake in Definium Therapeutics during the 3rd quarter valued at $286,000. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.